OUR TEAM
Darrick Carter, Ph.D.
Dr. Carter is the President and CEO of Protein Advances Incorporated. He received his B.S. from Oregon
State University and his Ph.D. from the Oregon Health Sciences Center. After his training in biochemistry
and biophysics he worked at Corixa Corp. (now GSK Bio). At Corixa his contributions included leading a new
TB vaccine into human clinical trials and assisting as group leader for analytical biochemistry in the
regulatory filings for commercial approval of Bexxar™, a radiolabeled antibody for non-Hodgkins lymphoma.
He started Protein Advances Incorporated in 2005, and the company now has contracts and patents in the fields
of biodefense and diagnostics.
Malcolm Duthie, Ph.D.
Dr. Duthie directs research as part of Protein Advances Inc.’s diagnostic program. Malcolm's research
goals are to develop improved and earlier diagnosis of infection, in conjunction with improved treatments,
for their practical application within disease control programs.
Malcolm obtained a BSc (Hons) Immunology degree from the University of Glasgow, Scotland, in 1996. His
postgraduate studies were performed at the University of Edinburgh in the laboratory of Professor Mary Norval.
During his time in Edinburgh, Malcolm acted as a tutor in the departments of Immunology, Medical Microbiology
and Medicine, and also served as the secretary of the Edinburgh University Medical Microbiology Society.
His PhD thesis, entitled "Local Effects of Ultraviolet Radiation on Cutaneous Immune Responses," was
completed in December 1999. He then moved to the University of Washington to examine protective and
pathologic immune responses during experimental T. cruzi infection and helped transition this work to
Infectious Disease Research Institute (IDRI) in 2002. In 2006, Malcolm shifted focus to a leprosy vaccine
development program and continues to work with collaborators in several countries to identify vaccine
candidates to improve the treatment of leprosy. As an extension of this goal, Malcolm joined Protein Advances Inc.
in 2008 to oversee development of a leprosy diagnostic test and to expand research to the diagnosis
of other pathogens.
Malcolm is currently a member of the American Association of Immunologists (AAI),
American Microbiology Society (ASM) and British Society for Immunology (BSI). In 2007 Malcolm gave the
keynote seminar at the annual meeting of the Brazilian Leprosy Society.
Cecile Morales
Cecile joined Protein AI as a Senior Research Associate in 2009. Prior to this, her focus was the
synthesis of potential bio-therapeutics, specifically antibody derivatives at Trubion Pharmaceuticals.
This followed a 5 year study of the molecular biology behind connective tissue disorders and being part
of the Immunex team that helped produce Enbrel for clinical trials. She earned her BS from the
University of Washington, Department of Biochemistry.
Overall, she is grateful to have worked with amazing scientists that helped her think critically with a
creative twist. She takes inspiration from them, her home, and her family.
Marah Hay
After graduating from Seattle University with a B.S. in biology, Marah Hay joined Protein AI as a
research associate. During her undergrad she discovered new operonic pairs in TB for an ongoing
research project. She is now currently working on the development of new diagnostic antigens for
both leprosy and African sleeping sickness.
Ruth Mann
Ruth joined Protein AI in 2009 as the
Head of Sales and Operations. She received her Master of Science at the
University of Aachen, Department Juelich, in Germany. Her background includes
working in pharmaceuticals, environmental services for hazardous waste, and as a
Branch Office Manager at ATV Ausbildung Training Vernetzung GmbH, Cologne, a
business school for marketing, sales and project management.
Nick Arnold
Nick joined Protein AI as a member of Computational Biology. He received his B.S. in Computer Science
from Seattle University in 2008. Nick worked in undergraduate research collaborating with Dr.
Robert Rutherford in predicting genomic transcriptional sites in mycobacterium tuberculosis. During his
time at Protein AI Nick develops software for compressing proteomic data as well as maintains the LabKey
Server System for the Infectious Disease Research Institute.
This website includes certain statements, estimates and projections with respect to the anticipated future performance of Protein Advances Inc. Such statements, estimates or projections reflect various assumptions, which assumptions may or may not prove to be correct. No representations are made as to the accuracy of such statements, estimates or projections. The Company does not undertake any obligation to provide additional information or to update any of the information set forth in this web site.>
© Copyright 2010 Protein Advances Inc.